XTX Topco Ltd Makes New $267,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

XTX Topco Ltd bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 31,573 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000. XTX Topco Ltd owned approximately 0.06% of KalVista Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after acquiring an additional 104,716 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of KalVista Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after purchasing an additional 24,713 shares in the last quarter. Schroder Investment Management Group grew its stake in shares of KalVista Pharmaceuticals by 86.8% in the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock worth $6,758,000 after buying an additional 374,213 shares during the last quarter. Russell Investments Group Ltd. increased its position in KalVista Pharmaceuticals by 15.2% during the 4th quarter. Russell Investments Group Ltd. now owns 133,572 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 17,580 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company’s stock valued at $1,041,000 after buying an additional 4,940 shares during the last quarter.

KalVista Pharmaceuticals Trading Up 0.9 %

NASDAQ:KALV opened at $12.99 on Friday. The company has a market cap of $645.81 million, a PE ratio of -3.57 and a beta of 0.39. The company has a 50 day simple moving average of $11.61 and a two-hundred day simple moving average of $10.36. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KALV shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Finally, JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.83.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was bought at an average cost of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the transaction, the insider now owns 4,986,480 shares of the company’s stock, valued at $43,681,564.80. This represents a 0.88 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the transaction, the insider now owns 100,334 shares in the company, valued at $985,279.88. The trade was a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 261,055 shares of company stock valued at $2,397,646 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by corporate insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).